文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症患者产AmpC酶肠杆菌科细菌所致呼吸机相关性肺炎的抗生素目标治疗:一项前瞻性多中心观察性研究

Antibiotic definitive treatment in ventilator associated pneumonia caused by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter observational study.
PubMed 文献 · Crit Care · 2024-02-05
一句话结论产野生型AmpC酶肠杆菌科VAP目标治疗选药与第7天治疗成功无关,但头孢三代目标治疗与第28天复发风险升高相关(csHR 10.9)。

该前瞻性多中心观察性研究纳入法国20个ICU连续274例野生型AmpC酶肠杆菌科细菌所致VAP患者,评估目标抗菌药物选择(哌拉西林±他唑巴坦、第三代头孢菌素或其他药物)与第7天治疗成功的关系。三组第7天成功率相似(74% vs. 73% vs. 68%,p=0.814)。第28天复发概率在哌拉西林±他唑巴坦组为31%(95%CI 21-42)、第三代头孢菌素组40%(95%CI 26-55)、对照组21%(95%CI 15-28)(p=0.020)。多因素分析中目标治疗选择与临床成功无关,但第三代头孢菌素目标治疗与第28天复发相关(csHR 10.9,95%CI 1.92-61.91)。

要点

  • 产野生型AmpC酶肠杆菌科VAP患者第7天治疗成功率:哌拉西林±他唑巴坦组74%、第三代头孢菌素组73%、对照组68%(p=0.814),三组相似。
  • 第28天复发概率:哌拉西林±他唑巴坦组31%(95%CI 21-42)、第三代头孢菌素组40%(95%CI 26-55)、对照组21%(95%CI 15-28),p=0.020。
  • 多因素分析中第三代头孢菌素目标治疗与第28天复发相关,csHR 10.9(95%CI 1.92-61.91)。
  • 目标抗菌药物选择与第7天临床成功无关,各组死亡率或机械通气时间无差异。
  • 阴沟肠杆菌为最常见病原体(31%),研究纳入法国20个ICU连续病例。

适用人群与场景

  • 法国20个ICU连续纳入的野生型AmpC酶肠杆菌科细菌所致呼吸机相关性肺炎(VAP)成人重症患者。

处置流程与药物剂量

  • 目标抗菌药物包括哌拉西林±他唑巴坦(PTZ)、第三代头孢菌素(3GCs)或其他药物(第四代头孢菌素、碳青霉烯类、喹诺酮类、复方磺胺甲噁唑;对照组)。
  • 尽管证据水平低,指南不鼓励使用第三代头孢菌素或哌拉西林作为目标抗菌治疗。

研究设计与关键结果

  • 前瞻性多中心观察性研究,2021年2月至2022年6月法国20个ICU连续纳入274例野生型AmpC酶肠杆菌科VAP患者;阴沟肠杆菌最常见(31%)。
  • 目标治疗分布:哌拉西林±他唑巴坦78例(28%)、第三代头孢菌素44例(16%)、对照组152例(56%)。
  • 第7天治疗成功率:哌拉西林±他唑巴坦组74% vs. 第三代头孢菌素组73% vs. 对照组68%,p=0.814。
  • 第28天复发概率:哌拉西林±他唑巴坦组31%(95%CI 21-42) vs. 第三代头孢菌素组40%(95%CI 26-55) vs. 对照组21%(95%CI 15-28),p=0.020。
  • 多因素分析:目标抗菌药物选择与临床成功无关;第三代头孢菌素目标治疗与第28天复发相关,csHR 10.9(95%CI 1.92-61.91)。
  • 死亡率或机械通气时间无差异。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于野生型AmpC酶肠杆菌科细菌所致VAP,目标治疗选择哌拉西林±他唑巴坦、第三代头孢菌素或其他药物对第7天治疗成功无差异。
  • 使用第三代头孢菌素作为目标治疗与第28天复发风险升高相关(csHR 10.9,95%CI 1.92-61.91),但死亡率或机械通气时间无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ventilator associated pneumonia (VAP) due to wild-type AmpC-producing Enterobacterales (wtAE) is frequent in intensive care unit (ICU) patients. Despite a low level of evidence, definitive antimicrobial therapy (AMT) with third generation cephalosporins (3GCs) or piperacillin is discouraged.

METHODS: Observational prospective study including consecutive wtAE VAP patients in 20 French ICUs. The primary objective was to assess the association of the choice of definitive AMT, i.e. piperacillin ± tazobactam (PTZ), 3GCs or other molecule (4GCs, carbapenems, quinolones, cotrimoxazole; control group), with treatment success at day-7. Recurrence of infection was collected as a secondary outcome, and analyzed accounting for the competing risk of death.

RESULTS: From February 2021 to June 2022, 274 patients were included. Enterobacter cloacae was the most prevalent specie (31%). Seventy-eight patients (28%) had PTZ as definitive AMT while 44 (16%) had 3GCs and 152 (56%) were classified in the control group. Day-7 success rate was similar between the 3 groups (74% vs. 73% vs. 68% respectively, p = 0.814). Recurrence probability at day-28 was 31% (95% CI 21-42), 40% (95% CI 26-55) and 21% (95% CI 15-28) for PTZ, 3GCs and control groups (p = 0.020). In multivariable analysis, choice of definitive AMT was not associated with clinical success, but definitive AMT with 3GCs was associated with recurrence at day-28 [csHR(95%CI) 10.9 (1.92-61.91)].

CONCLUSION: Choice of definitive antimicrobial therapy was not associated with treatment success at day 7. However, recurrence of pneumonia at day-28 was higher in patients treated with third generation cephalosporins with no differences in mortality or mechanical ventilation duration.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Petit M, Bidar F, Fosse Q, et al. Antibiotic definitive treatment in ventilator associated pneumonia caused by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter observational study. Crit Care. 2024. PMID: 38317262. doi:10.1186/s13054-024-04820-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。